Research programme: vascular endothelial growth factor receptor 3 antagonists - Sareum

Drug Profile

Research programme: vascular endothelial growth factor receptor 3 antagonists - Sareum

Alternative Names: Research programme: FLT4 antagonists - Sareum

Latest Information Update: 28 Jul 2016

Price : $50

At a glance

  • Originator Sareum
  • Class Small molecules
  • Mechanism of Action Vascular endothelial growth factor receptor 3 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • No development reported Cancer

Most Recent Events

  • 28 Jul 2016 No reports on development identified - Preclinical for Cancer in United Kingdom (PO)
  • 09 Dec 2010 Research programme: vascular endothelial growth factor receptor 3 antagonists - Sareum is available for licensing as of 09 Dec 2010. http://www.sareum.co.uk
  • 15 Feb 2010 Preclinical development is ongoing in UK
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top